November 25, 2014 5:24 PM ET

Biotechnology

Company Overview of Genocea Biosciences, Inc.

Company Overview

Genocea Biosciences, Inc., a clinical stage biotechnology company, discovers and develops novel vaccines to treat infectious diseases. It uses its proprietary discovery platform, AnTigen Lead Acquisition System, to design vaccines that act through T cell immune responses. The company is developing its lead product candidate, GEN-003, a therapeutic vaccine or an immunotherapy that is in Phase I/IIa trial to treat people with herpes simplex virus-2 (HSV-2) infections. It is also developing GEN-004, a vaccine candidate, which is in Phase I trial to prevent infections caused by pneumococcus; GEN-001 that is in pre-clinical stage for treating chlamydia prophylaxis; GEN-002, which is in pre-clinic...

100 Acorn Park Drive

5th Floor

Cambridge, MA 02140

United States

Founded in 2006

44 Employees

Phone:

617-876-8191

Key Executives for Genocea Biosciences, Inc.

Chief Executive Officer
Age: 45
Total Annual Compensation: $334.3K
Chief Medical Officer
Age: 62
Total Annual Compensation: $331.5K
Senior Vice President of Research
Age: 42
Total Annual Compensation: $238.3K
Vice President of Biopharmaceutical Development & Production
Age: 51
Total Annual Compensation: $257.3K
Compensation as of Fiscal Year 2013.

Genocea Biosciences, Inc. Key Developments

Genocea Biosciences Secures Debt Facility from Hercules Technology Growth Capital of Up to $27 Million

Genocea Biosciences, Inc. announced that it has entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. for a term loan of up to $27.0 million. The proceeds of the initial draw of $12.0 million will be used to repay Genocea's existing term loan facility and to provide additional working capital for general corporate purposes. Genocea can draw up to an additional $5.0 million at its option through June 30, 2015. Two further tranches of $5.0 million each can be drawn down at Genocea's option on or prior to December 15, 2015 subject to the achievement of certain clinical and corporate milestones.

Genocea Biosciences, Inc. Presents at Stifel Healthcare Conference 2014, Nov-19-2014 10:20 AM

Genocea Biosciences, Inc. Presents at Stifel Healthcare Conference 2014, Nov-19-2014 10:20 AM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: William D. Clark, Chief Executive Officer, President and Director.

Genocea Biosciences, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Genocea Biosciences, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported that loss from operations was $8,958,000 compared to $4,475,000 a year ago. Net loss was $9,171,000 compared to $4,839,000 a year ago. Net loss attributable to common stockholders was $9,171,000 or $0.53 per basic and diluted share compared to $5,243,000 or $17.71 per basic and diluted share a year ago. For the nine months, the company reported that loss from operations was $22,240,000 compared to $13,756,000 a year ago. Net loss was $23,646,000 compared to $14,460,000 a year ago. Net loss attributable to common stockholders was $23,826,000 or $1.60 per basic and diluted share compared to $15,660,000 or $52.91 per basic and diluted share a year ago.

Similar Private Companies By Industry

Company Name Region
Kalion, Inc. United States
Akron Biotechnology, LLC United States
Enterix Inc. United States
Progression Therapeutics, Inc. United States
Etubics Corporation United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
November 20, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Genocea Biosciences, Inc., please visit www.genocea.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.